History Catches Up With Merck Via FDA Actions
Sunday, May 4th, 2008Merck, maker of Vioxx and owner of a $4.5 Billion USD payout for the same medication’s class-action and private lawsuits is now facing greater scrutiny from the Food and Drug Administration at every turn. Within the past three weeks, Merck has had to deal with two of its experimental prescription drugs being rejected by the FDA at the hint of trouble, and now they are being ordered to complete significant cleanup at their plants.
Shares of Merck are down over 30% since last January when their cholesterol-fighting drug, set to be the next generation of Zocor, was deemed “unapprovable” by regulators. The medication, named Cordaptive, cleared trials but was rejected on the grounds that it was no better and more expensive than other medications. This has caused a financial ruckus that has caused Merck to cut over 7,000 jobs.
Not since Merck was forced to pull Vioxx has the market turned so sour for them. One can only point at their history and the egg-on-the-face look that the FDA got from passively approving so many other prescription medications from the company that have backfired and caused countless prescription Drug lawsuits.
http://finance.sympatico.msn.ca/investing/news/businessnews/article.aspx?cp-documentid=7121644
Source: MSN Canada
Subscribe to our daily news feed